Contact
QR code for the current URL

Story Box-ID: 75017

Signature Diagnostics AG Hermannswerder 20 A 14473 Potsdam, Germany http://www.signature-diagnostics.de
Contact Prof. Dr. André Rosenthal +49 331 6207575
Company logo of Signature Diagnostics AG
Signature Diagnostics AG

Signature Diagnostics announces a Clinical Research Collaboration with OncoMethylome Sciences

(PresseBox) (Potsdam, )
Signature Diagnostics announces today that it has entered into a Clinical Research Collaboration in the field of colorectal cancer (CRC) with OncoMethylome Sciences to make available its clinical CRC platform for the development and validation of new molecular diagnostics. OncoMethylome Sciences is a public diagnostic company with offices in Liege, Leuven (Belgium), Amsterdam (the Netherlands) and Durham (NC; USA).

Starting immediately Signature Diagnostics will provide OncoMethylome Sciences with prospective tissue samples including tumor samples, plasma and stool samples as well as associated clinical data from CRC patients from all four stages of the disease.

Prof. André Rosenthal, Chief Executive Officer of Signature Diagnostics, states: "We are pleased that OncoMethylome Sciences has recognized the value of our clinical technology platform and our capability to run large multi-center prospective diagnostic trials within Germany. I am convinced that our collaboration will accelerate the validation and development of novel diagnostic products both at OncoMethylome Sciences and Signature Diagnostics. Prospective tissue sample collections are an essential component of the development of novel genomics-based diagnostics and we are excited to be able to collaborate with OncoMethylome Sciences in this strategic field." Financial figures are not disclosed.

Signature Diagnostics AG

Signature Diagnostics AG (www.signature-diagnostics.de) is a molecular diagnostic company dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer. Signature believes that patient selection and stratification based on gene signatures will soon become an important component of routine cancer treatment. Signature improves the quality of decision making in cancer treatment and patient care.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.